ArticleObesity (Silver Spring, Md.)2019
Patient Characteristics Associated with Receipt of Prescription Weight-Management Medications Among Veterans Participating in MOVE!
Article in Obesity (Silver Spring, Md.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- Testing a tailored weight management program for veterans with PTSD: The MOVE! + UP randomized controlled trial.Contemporary clinical trials · 2021Trial
- Receipt of Weight Management Services Among Patients With OSA and Obesity.CHEST pulmonary · 2025Article
- Patient, facility, and environmental factors associated with obesity treatment in US Veterans.Obesity science & practice · 2024Article
- Weight Loss Outcomes in a Veterans Affairs Pharmacotherapy-based Weight Management Clinic.Journal of the Endocrine Society · 2024Article
- Phentermine in the Modern Era of Obesity Pharmacotherapy: Does It Still Have a Role in Treatment?Current obesity reports · 2024Review
- Real World Use of Anti-Obesity Medications and Weight Change in Veterans.Journal of general internal medicine · 2024Article
- Use of medications associated with weight change among participants in the All of Us research programme.Clinical obesity · 2023Article
- "Anti-obesity medications" or "medications to treat obesity" instead of "weight loss drugs" - why language matters - an official statement of the Brazilian Association for the Study of Obesity and Metabolic Syndrome (ABESO) and the Brazilian Society of Endocrinology and Metabolism (SBEM).Archives of endocrinology and metabolism · 2023Article
- Obesity treatment initiation, retention, and outcomes in the Veterans Affairs MOVE! Program among rural and urban veterans.Obesity science & practice · 2022Article
- Sex/Gender Differences in Obesity Prevalence, Comorbidities, and Treatment.Current obesity reports · 2021Review
- Sex- and Gender-Based Pharmacological Response to Drugs.Pharmacological reviews · 2021Article
- Obesity Pharmacotherapy is Effective in the Veterans Affairs Patient Population: A Local and Virtual Cohort Study.Obesity (Silver Spring, Md.) · 2021Article
- The limits and challenges of antiobesity pharmacotherapy.Expert opinion on pharmacotherapy · 2020Review
- Testing a self-directed lifestyle intervention among veterans: The D-ELITE pragmatic clinical trial.Contemporary clinical trials · 2020Article
- Eating Disorders and Overweight/Obesity in Veterans: Prevalence, Risk Factors, and Treatment Considerations.Current obesity reports · 2020Review
- Anorectic state of obesity medications in the United States. Are leaner times ahead?Expert opinion on pharmacotherapy · 2020Review
Corrections and comments
- Commented on by
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveWeight-management medications (WMM) are recommended for the treatment of obesity. This study examined characteristics associated with initial receipt of WMM among eligible veterans in the first year following enrollment in the Veterans Health Administration (VHA) MOVE! behavioral weight-management program.
methodsWe conducted a retrospective cohort study of VHA patients with obesity or overweight and obesity-related comorbidities who enrolled in MOVE! from October 2013 to September 2016 (N = 153,939). Multivariable logistic regression models estimated predictors of having a filled prescription for WMM and for orlistat.
resultsA total of 1.1% of these veterans received WMM. The most common WMM included orlistat (70.4%), phentermine/topiramate (11.2%), and bupropion/naltrexone (9.7%). Female sex, higher BMI, obstructive sleep apnea, osteoarthritis, depression, lower back pain, and alcohol abuse were associated with greater odds of use of WMM, whereas age over 65 years, Hispanic ethnicity, and required co-payments were associated with lower odds. Among patients receiving WMM, older age, black race, female sex, higher BMI, cardiovascular disease, lower back pain, and congestive heart failure were associated with use of orlistat versus any other WMM.
conclusionsOf patients engaged in MOVE! in the VHA, 1.1% received WMM. WMM are underutilized among veterans. Additional research is needed to understand barriers to incorporating WMM into comprehensive obesity treatment plans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.